comparemela.com

Latest Breaking News On - International prognostic scoring system - Page 13 : comparemela.com

First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes

/PRNewswire/ Syntrix Pharmaceuticals today announced results from a single-arm, open-label Phase 1 trial of single-agent SX-682, an investigational CXCR1/2.

United statesDavid sallmanAaron schulerJohn zebalaH lee moffitt cancer centerSyntrix pharmaceuticalsAmerican society of hematologyResearch instituteInternational prognostic scoring systemNational heartBlood institutePrnewswire syntrix pharmaceuticalsOral sessionMeeting supportPromising targetPatients treated

Clinical Outcomes Similar With 5- or 7-Day Azacitidine in Lower-Risk Myelodysplastic Syndrome

Researchers determined the outcomes of patients with lower-risk MDS was similar with either a 5- or 7-day dosing schedule of azacitidine.

Bristol myers squibbInternational prognostic scoring system

Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS

About a third of patients, including those with <em>TP53</em> mutations, achieved complete remission

United statesDavida sallmanMike bassettUniversity of texas md anderson cancer centerInternational prognostic scoring systemMoffitt cancer centerSociety of hematologic oncologyNaval daverCancer centerHematologic oncology

Management and Survival Outcomes of Waldenström Macroglobulinemia in Latin America

Researchers retrospectively analyzed data from patients with WM in 7 Latin American countries to investigate the clinical, therapy, and outcome patterns.

United statesInternational prognostic scoring systemLatin america

Post-Transplantation Prognostic Model Developed for Myelodysplastic Syndromes

Researchers developed a clinical risk model for predicting outcomes of allogeneic transplant in patients with myelodysplastic syndromes.

International prognostic scoring systemRevised international prognostic scoring system

vimarsana © 2020. All Rights Reserved.